Explore INmune Bio's Q2 2025 earnings call: new CEO, strategic shifts, XPro's Alzheimer's pause, CORDStrom advancements, and a focus on partnerships.

Discover Vistagen's Q1 2026 progress! From Phase III trials of fasedienol to robust financial backing, explore its potential as a breakthrough in ...

SPG302, a Potential First-in-Class Synaptic Regenerative Therapy, Showed Progress in Cognitive Outcome Measures and a Favorable Safety Profile LOS ...

Results from the Phase III EPCORE FL-1 trial (NCT05409066) showed that patients treated with Epkinly (epcoritamab) in combination with Rituxan (rituximab) and Revlimid (lenalidomide) for relapsed or ...

Detailed price information for Cabaletta Bio Inc (CABA-Q) from The Globe and Mail including charting and trades.

Approval followed priority review and was based on response rates and duration of response demonstrated in the phase 1b ...

Detailed price information for Tectonic Therapeutic Inc (TECX-Q) from The Globe and Mail including charting and trades.

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Welcome to the Lisata Therapeutics Second Quarter 2025 Financial ...

Q2 2025 Earnings Call Transcript August 8, 2025 Operator: Greetings, and welcome to at Avadel Pharmaceuticals Second Quarter 2025 Earnings Call. [Operator Instructions]. Accompanying slides for this ...

PureWow editors select every item that appears on this page, and some items may be gifted to us. Additionally, PureWow may ...

One of the highlights of the event is the special finisher's prize. Since the 2025 race, each finisher receives an individually handcrafted crystal tumbler made by Baccarat, a French luxury brand with ...

Construction is complete at Big Whiskey’s American Restaurant and Bar, and the locally owned downtown spot is set to hold its ...